# Functional siRNA Screen Links Ras/MAPK and Wnt Pathway to EV Secretion in HCT-116 Colorectal Cancer Cells

**Authors:** Sophie Marie Pätzold, Julia Christina Gross

PMC · DOI: 10.3390/diseases14030089 · 2026-03-02

## TL;DR

This study shows that genes in the Ras/MAPK and Wnt pathways influence how much extracellular vesicles are released by colorectal cancer cells.

## Contribution

The study identifies specific cancer-related genes linked to extracellular vesicle secretion in colorectal cancer cells.

## Key findings

- KRAS and BRAF knockdown increased EV secretion and altered EV characteristics.
- CTNNB1 and CDH1 knockdown affected EV secretion in distinct ways.
- No clear difference was found between tumor suppressor genes and oncogenes in their effect on EV secretion.

## Abstract

Background: Extracellular vesicles (EVs) play an important role in tumor progression and intercellular communication, yet the contribution of specific cancer-related genes to EV secretion remains incompletely defined. Methods: To address this, we performed an siRNA-based loss-of-function screen targeting 30 frequently altered (proto-)oncogenes and tumor suppressor genes in the colorectal carcinoma cell line HCT-116 to assess their impact on EV release. EVs were isolated by sequential ultracentrifugation to obtain P14 and P100 fractions pelleting at 14,000× g or 100,000× g, respectively, and were characterized by nanoparticle tracking analysis, EV marker expression, and total protein quantification. Cell viability was assessed to control for potential apoptosis-related effects. Results: With few exceptions, knockdown of the investigated genes led to an increase in EV secretion. Silencing of KRAS and BRAF resulted in significantly elevated P14 EV levels, increased EV marker expression, and higher total protein content, while KRAS knockdown was additionally associated with a shift toward larger particle sizes. Downregulation of CTNNB1 increased P14 and decreased P100 EV secretion, whereas CDH1 knockdown reduced P14 EV levels and slightly increased P100 EVs. No general distinction between tumor suppressor genes and (proto-)oncogenes regarding their effects on EV secretion was observed, and cell viability was not significantly altered under the experimental conditions. Conclusions: These findings suggest that components of the Ras/Raf/MAPK and Wnt signaling pathways may contribute to the regulation of EV secretion in colorectal cancer cells.

## Linked entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845], BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673], CTNNB1 (catenin beta 1) [NCBI Gene 1499], CDH1 (cadherin 1) [NCBI Gene 999]
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, PKM (pyruvate kinase M1/2) [NCBI Gene 5315] {aka CTHBP, HEL-S-30, OIP3, PK3, PKM2, TCB}, BSG (basigin (Ok blood group)) [NCBI Gene 682] {aka 5F7, CD147, EMMPRIN, EMPRIN, HAb18G, OK}, Kras (KRAS proto-oncogene, GTPase) [NCBI Gene 24525] {aka K-ras, Kras2, c-Ki-ras, p21}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, CANX (calnexin) [NCBI Gene 821] {aka CNX, IP90, P90}, SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657] {aka ANOP3, MCOPS3}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, PDCD6IP (programmed cell death 6 interacting protein) [NCBI Gene 10015] {aka AIP1, ALIX, DRIP4, HP95, MCPH29}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, TSG101 (tumor susceptibility 101) [NCBI Gene 7251] {aka TSG10, VPS23}, GOLGA2 (golgin A2) [NCBI Gene 2801] {aka DEDHMB, GM130}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, FLOT1 (flotillin 1) [NCBI Gene 10211], HRAS (HRas proto-oncogene, GTPase) [NCBI Gene 3265] {aka C-BAS/HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX, HAMSV}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, GSTP1 (glutathione S-transferase pi 1) [NCBI Gene 2950] {aka DFN7, FAEES3, GST3, GSTP, GSTP1-1, HEL-S-22}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, RAB13 (RAB13, member RAS oncogene family) [NCBI Gene 5872] {aka GIG4}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, NFKB2 (nuclear factor kappa B subunit 2) [NCBI Gene 4791] {aka CVID10, H2TF1, LYT-10, LYT10, NF-kB2, p100}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, CD81 (CD81 molecule) [NCBI Gene 975] {aka CVID6, S5.7, TAPA1, TSPAN28}, TP63 (tumor protein p63) [NCBI Gene 8626] {aka AIS, B(p51A), B(p51B), EEC3, KET, LMS}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}
- **Diseases:** Cancer (MESH:D009369), EV (MESH:C535509), blood coagulation (MESH:D001778), melanoma (MESH:D008545), Colorectal Cancer (MESH:D015179), carcinogenesis (MESH:D063646), brain metastasis (MESH:D009362), injury to (MESH:D014947)
- **Chemicals:** glucose (MESH:D005947), water (MESH:D014867), PEP (MESH:D010728), CO2 (MESH:D002245), ATP (MESH:D000255), PBS (MESH:D007854), GTP (MESH:D006160), penicillin (MESH:D010406), phosphate (MESH:D010710), ROS (MESH:D017382), lipid (MESH:D008055), EDTA (MESH:D004492), ADP (MESH:D000244), SDS (MESH:D012967), GDP (MESH:D006153), carbons (MESH:D002244), CASYton (-), streptomycin (MESH:D013307), PVDF (MESH:C024865), calcium (MESH:D002118)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** serine/threonine, G13D, S45 del, H1047R, Y103H, H121Tfs*94, L238Yfs*25
- **Cell lines:** ACC 581 — Homo sapiens (Human), Medulloblastoma, Cancer cell line (CVCL_7900), HCT-116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), DSMZ.de — Homo sapiens (Human), Ehlers-Danlos syndrome, type III, Finite cell line (CVCL_3322)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025452/full.md

---
Source: https://tomesphere.com/paper/PMC13025452